The Governing Council of the University of Toronto

The AAAI-24 Workshop Program, sponsored by the Association for the Advancement of Artificial Intelligence, features a series of workshops focusing on various AI topics. Key workshops include discussions on Large Language Models (LLMs) causality, AI for credible elections, digital human creation, AI in education, finance for social impact, AI in science and engineering, AI-based planning for cyber-physical systems, brain encoding and decoding with AI, cybersecurity, operations research, time series analysis, cognitive and mental health, neuro-symbolic learning, privacy-preserving AI, public sector LLMs, recommendation ecosystems, responsible language models, and scientific document understanding. Each workshop aims to bring together researchers and practitioners to discuss advancements, challenges, and applications in their respective fields.

A compound developed at the Milwaukee Institute for Drug Discovery (MIDD) is set to enter clinical trials at the FDA, potentially leading to a new treatment for depression and Alzheimer's. The drug, GL-Damonia, shows promise in restoring brain cell growth in mice, with no toxicity observed. If successful, it could also treat schizophrenia. The trials involve testing safety in healthy individuals (Phase 1), efficacy in patients (Phase 2), and large-scale effectiveness (Phase 3). Despite the high costs and low success rate, researchers remain motivated by the potential to help patients.

Viatris launches Viagra ODF, an orodispersible film for ED treatment in Canada, offering convenience and discretion, with a 50 mg dose at similar pricing to Viagra tablets.

Duke-NUS scientists found that glucagon receptor blockers improve heart function in HFpEF, a common but challenging heart condition, by reducing heart stiffness and enhancing relaxation.

Glioblastoma, the most aggressive brain cancer, has a 14-month survival rate and a 90% recurrence rate. Traditional treatments like surgery, chemotherapy, and radiation are ineffective. Tumour Treating Fields (TTFs) show promise but are unwieldy. Glioblastoma-on-a-chip platforms mimic GBM cells for personalized medicine. Wireless brain implants using heated nanoparticles offer a non-invasive, at-home treatment alternative, targeting cancer cells without open-skull surgeries or harsh side effects.

The article discusses the importance of summarizing content accurately and concisely, focusing on clarity and retaining original expressions.

NIH lab mimics bar to study if anti-obesity drugs curb alcohol cravings; evidence suggests GLP-1 receptor agonists may reduce various addictions. Clinical trials underway, with potential benefits beyond weight loss, including reducing cardiovascular risks, easing sleep apnoea, and slowing Parkinson’s development. Understanding drug mechanisms could optimize responses and mitigate side effects.

Epineuron announces Health Canada approval of its PeriPulse™ nerve regeneration system, designed to enhance nerve regeneration for severe injuries and chronic conditions. The device uses advanced shapeable electrodes and a wearable for quick deployment, reducing operating room time by 95%. Ongoing trials REGAIN™ and SELECT™ focus on nerve lacerations and compression injuries, respectively.

Synex Medical, founded by Ben Nashman, aims to develop a portable MRI for non-invasive glucose testing, raising $21.8 million in Series A funding. The prototype, currently toaster-sized, uses MRI and magnetic resonance spectroscopy to track glucose and other molecules. Despite challenges, Nashman's vision is to create a device small enough for personal use, revolutionizing diabetes care and predictive medicine.

FDA approves ribociclib for HR+/HER2– breast cancer, AMG 193 shows activity in MTAP-deleted tumors, pembrolizumab plus chemo for mesothelioma, neoadjuvant pembrolizumab/chemo boosts OS in TNBC, and experts discuss 2024 IASLC World Conference on Lung Cancer findings.